A similar case by Okan et al. in 2023 reported a 62-year-old male with LVNC presenting for arrhythmia evaluation, managed with beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, and later sacubitril/valsartan, showing improvement in left ventricular ejection fraction (LVEF) over five years of follow-up [12]. This evidence concerns the gene ACE and left ventricular noncompaction.